Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial-Reference-Cited by-同舟云学术

Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial

Published:2024-08 Issue:8 Volume:9 Page:734-744
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Vogel Arndt,Saborowski Anna,Wenzel Patrick,Wege Henning,Folprecht Gunnar,Kretzschmar Albrecht,Schütt Philipp,Jacobasch Lutz,Ziegenhagen Nicolas,Boeck Stefan,Zhang Danmei,Kanzler Stephan,Belle Sebastian,Mohm Johannes,Gökkurt Eray,Lerchenmüller Christian,Graeven Ullrich,Pink Daniel,Götze Thorsten,Kirstein Martha M

Publisher

Elsevier BV

Reference24 articles.

1. Aspirin use and the risk of cholangiocarcinoma;Choi;Hepatology,2016

2. Cholangiocarcinoma 2020: the next horizon in mechanisms and management;Banales;Nat Rev Gastroenterol Hepatol,2020

3. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Vogel;Ann Oncol,2023

4. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry;Izquierdo-Sanchez;J Hepatol,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New perspectives in biliary tract cancers;ESMO Gastrointestinal Oncology;2024-09

2. Nanoliposomal irinotecan in advanced biliary tract cancers;The Lancet Gastroenterology & Hepatology;2024-08